pde4d7

FCPR03 is a selective inhibitor of phosphodiesterase 4 (PDE4) with IC50s of 31 nM, 47 nM, and 60 nM for PDE4B1, PDE4D7, and PDE4 catalytic domain, respectively. FCPR03 has neuroprotective, anti-inflammatory, and antidepressant-like effects.

Zatolmilast (BPN14770) is an allosteric inhibitor of selective phosphodiesterase 4D (PDE4D; IC50s: 7.8 nM and 7.4 nM for PDE4D7 and PDE4D3).

Z19153 is a PDE4 inhibitor with IC50 values of 110 nM for PDE4B1 and 1160 nM for PDE4D7. It exhibits significant hepatoprotective effects in cases of hepatic sepsis.

Z21115 is an orally effective phosphodiesterase 4 (PDE4) inhibitor that can inhibit PDE4D7 with an IC50 of 10.5 nM. It suppresses the expression of IL-6, TNF-α, and iNOS induced by Lipopolysaccharide. In a DSS-induced mouse colitis model, Z21115 demonstrates anti-inflammatory activity without significant toxicity at doses up to 1 g kg.

LEO-32731 is a bioactive chemical.